NCVI Enterprises Increases IOL Chemicals Stake with Additional Share Acquisition

IOL Chemicals & Pharmaceuticals Limited disclosed that its promoter group entity NCVI Enterprises Limited has made multiple equity share acquisitions through open market transactions, as per regulatory filings under SEBI's Prohibition of Insider Trading Regulations, 2015.

Recent Transaction Details

The latest acquisition involved NCVI Enterprises Limited purchasing 4,04,305 equity shares on 19th March 2026, valued at ₹3,01,44,163. This transaction was disclosed to stock exchanges on 20th March 2026.

Transaction Parameter:	Latest Acquisition	Previous Acquisition
Shares Acquired:	4,04,305	7,00,000
Transaction Value:	₹3,01,44,163	₹5,14,08,739
Acquisition Date:	19th March 2026	18th March 2026
Mode:	On Market	On Market
Disclosure Date:	20th March 2026	19th March 2026

Shareholding Pattern Evolution

Following the recent acquisition, NCVI Enterprises Limited's direct shareholding in IOL Chemicals has increased from 4,82,50,695 shares to 4,86,55,000 shares, representing a change from 16.44% to 16.58% of the total equity.

Shareholding Position:	Before Latest Transaction	After Latest Transaction
NCVI Enterprises Shares:	4,82,50,695	4,86,55,000
Percentage Holding:	16.44%	16.58%
Change:	-	+0.14%

Regulatory Compliance Framework

The disclosures were made under Regulation 7(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015, and submitted to both National Stock Exchange and BSE Limited. The latest filing was signed by Abhiraj Gupta, Director of NCVI Enterprises Limited, and communicated through IOL Chemicals' Company Secretary Abhay Raj Singh.

Company Structure

IOL Chemicals and Pharmaceuticals Limited operates with equity shares of ₹2 each, maintaining listings on both major Indian stock exchanges with trading symbol IOLCP on NSE and security code 524164 on BSE. NCVI Enterprises Limited continues to be a key promoter group entity with increasing stake in the pharmaceutical company.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.18%	-1.65%	+5.80%	-27.76%	+21.24%	-30.04%

IOL Chemicals & Pharmaceuticals Limited has disclosed that its promoter group entity, Mayadevi Polycot Limited, has increased its shareholding in the company through an on-market acquisition. The transaction, completed on March 18, 2026, was disclosed under Regulation 7(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015.

Latest Transaction Details

The recent shareholding acquisition involved a purchase of equity shares by Mayadevi Polycot Limited on March 18, 2026:

Parameter:	Details
Shares Acquired:	54,197 equity shares
Transaction Value:	₹40,00,210
Transaction Date:	March 18, 2026
Mode of Acquisition:	On Market
Transaction Type:	Buy

Updated Shareholding Position

The acquisition has resulted in an increase in Mayadevi Polycot Limited's individual stake in IOL Chemicals and Pharmaceuticals Limited:

Shareholding Position:	Before Transaction	After Transaction
Mayadevi Polycot Shares:	6,38,91,133	6,39,45,330
Individual Percentage:	21.76%	21.78%
Change:	-	+0.02%

The increase of 0.02 percentage points in shareholding reflects the promoter group entity's continued investment in the company.

Regulatory Compliance and Disclosure

The disclosure was made in accordance with Regulation 7(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015. IOL Chemicals and Pharmaceuticals Limited communicated this information to both the National Stock Exchange of India Limited (NSE) and BSE Limited on March 19, 2026.

Regulatory Details:	Information
NSE Symbol:	IOLCP
BSE Security Code:	524164
Company ISIN:	INE485C01029
Disclosure Date:	March 19, 2026
Signatory:	Varinder Gupta, Director (DIN: 00044068)

Company Structure

Mayadevi Polycot Limited is classified as a promoter group entity of IOL Chemicals and Pharmaceuticals Limited. The entity is based at 86 Industrial Area A, Ludhiana. The disclosure was signed by Varinder Gupta, Director of Mayadevi Polycot Limited, and countersigned by Abhay Raj Singh, Sr. Vice President & Company Secretary of IOL Chemicals and Pharmaceuticals Limited.

The transaction represents a strategic investment by the promoter group entity, demonstrating continued confidence in the company's prospects and reinforcing their commitment to the company's growth trajectory.